Blueprint Medicines (BPMC) Stock Price, News & Analysis

Company Overview

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $129.46 to $129.46
• 50-Day Range: $127.85 to $129.48
• 52-Week Range: $73.04 to $129.65
• Volume: N/A
• Average Volume: 1.55 million shs
• Market Capitalization: $8.36 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $130.00
• Consensus Rating: Hold

Blueprint Medicines Stock Analysis - MarketRank™

Blueprint Medicines scored higher than 17% of companies evaluated by MarketBeat, and ranked 873rd out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.1 / 5
• Analyst Rating: Hold

Consensus Rating

Blueprint Medicines has received a consensus rating of Hold. The company's average rating score is 2.11, and is based on 2 buy ratings, 16 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Blueprint Medicines has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Blueprint Medicines are expected to grow in the coming year, from ($1.28) to $0.65 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Blueprint Medicines is -52.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Blueprint Medicines is -52.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Blueprint Medicines has a P/B Ratio of 27.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.95% of the float of Blueprint Medicines has been sold short.

Short Interest Ratio / Days to Cover

Blueprint Medicines has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Blueprint Medicines has recently increased by 17.57%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Blueprint Medicines does not currently pay a dividend.

Dividend Growth

Blueprint Medicines does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.95% of the float of Blueprint Medicines has been sold short.

Short Interest Ratio / Days to Cover

Blueprint Medicines has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Blueprint Medicines has recently increased by 17.57%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Blueprint Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $869,050.00 in company stock.

Percentage Held by Insiders

Only 4.21% of the stock of Blueprint Medicines is held by insiders.

BPMC Stock Analysis - Frequently Asked Questions

How have BPMC shares performed this year?

Blueprint Medicines' stock was trading at $87.22 on January 1st, 2025. Since then, BPMC shares have increased by 48.4% and is now trading at $129.46.

How were Blueprint Medicines' earnings last quarter?

Blueprint Medicines Corporation (NASDAQ:BPMC) announced its earnings results on Thursday, May, 1st. The biotechnology company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by $0.32. Blueprint Medicines's revenue was up 55.5% compared to the same quarter last year.
Read the conference call transcript.

When did Blueprint Medicines IPO?

Blueprint Medicines (BPMC) raised $115 million in an initial public offering on Thursday, April 30th 2015. The company issued 7,200,000 shares at $15.00-$17.00 per share. Goldman Sachs and Cowen and Company served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are Blueprint Medicines' major shareholders?

Top institutional shareholders of Blueprint Medicines include State Street Corp (3.45%), OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC (2.65%), Geode Capital Management LLC (2.39%) and Norges Bank (1.66%). Insiders that own company stock include Kate Haviland, Jeffrey W Albers, Fouad Namouni, Christina Rossi, Tracey L Mccain, Percy H Carter, Michael Landsittel, Debra Durso-Bumpus, Christopher K Murray, Philina Lee, L Becker Hewes and Ariel Hurley.
View institutional ownership trends.

How do I buy shares of Blueprint Medicines?

Shares of BPMC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Blueprint Medicines own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Blueprint Medicines investors own include American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), Humana (HUM), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY).

Company Calendar

• Last Earnings: 5/01/2025
• Today: 8/14/2025
• Next Earnings (Estimated): 10/28/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BPMC
• CIK: 1597264
• Web: www.blueprintmedicines.com
• Phone: (617) 374-7580
• Fax: N/A
• Employees: 640
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Blueprint Medicines: $130.00
• High Price Target: $135.00
• Low Price Target: $119.00
• Potential Upside/Downside: +0.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.11
• Research Coverage: 18 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.47)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$67.09 million
• Net Margins: -27.70%
• Pretax Margin: -27.38%
• Return on Equity: -64.60%
• Return on Assets: -17.22%

Debt

• Debt-to-Equity Ratio: 1.01
• Current Ratio: 2.80
• Quick Ratio: 2.75

Sales & Book Value

• Annual Sales: $562.12 million
• Price / Sales: 14.87
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.70 per share
• Price / Book: 27.54

Miscellaneous

• Outstanding Shares: 64,582,000
• Free Float: 61,863,000
• Market Cap: $8.36 billion
• Optionable: Optionable
• Beta: 0.89